Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2017. doi: 10.1016/j.jacc.2017.10.054. [Epub ahead of print]
Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481-2488.
Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427-1436.
Piccini JP, Sr., Allen LA, Kudenchuk PJ, Page RL, Patel MR, Turakhia MP. Wearable Cardioverter-Defibrillator therapy for the prevention of sudden cardiac death: a science advisory from the American Heart Association. Circulation. 2016;133:1715-1727.
Bigger JT, Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997;337:1569-1575.
Olgin JE, Pletcher M, Vittinghoff E, et al. Efficacy of a Wearable Cardioverter-Defibrillator After Myocardial Infarction: Results of the Vest Prevention of Early Sudden Death Trial (VEST). Presented at: American College of Cardiology Annual Scientific Session. March 10, 2018; Orlando, FL. Abstract 401-10.
Epstein AE, Abraham WT, Bianco NR, et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction. J Am Coll Cardiol. 2013;62:2000-2007.
Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord. 2012;12:123.
Mitrani RD, McArdle A, Slane M, Cogan J, Myerburg RJ. Wearable defibrillators in uninsured patients with newly diagnosed cardiomyopathy or recent revascularization in a community medical center. Am Heart J. 2013;165:386-392.
Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2013;6:117-128.
Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail. 2012;18:21-27.
Rao M, Goldenberg I, Moss AJ, et al. Wearable defibrillator in congenital structural heart disease and inherited arrhythmias. Am J Cardiol. 2011;108:1632-1638.
Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol. 2010;56:194-203.
Wässnig NK, Günther M, Quick S, et al. Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation. 2016;134:635-643.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Sunil V. Rao, MD

Professor of Medicine, Duke University Medical Center; Section Chief, Cardiology, Durham VA Medical Center, Durham, North Carolina

Disclosures

Disclosure: Sunil V. Rao, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Corindus, Inc.; Medtronic, Inc.; Philips Healthcare; Volcano Corporation

Dr Rao does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Rao does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Anne B. Curtis, MD, MACP

SUNY Distinguished Professor; Charles and Mary Bauer Professor and Chair, Department of Medicine, University at Buffalo, Buffalo, New York

Disclosures

Disclosure: Anne B. Curtis, MD, MACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Novartis Pharmaceuticals Corporation; Sanofi
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Medtronic, Inc.

Dr Curtis does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Curtis does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Byron K. Lee, MD, MAS

Professor of Medicine; Samuel T. and Elizabeth Webb Reeves Endowed Chair in Arrhythmia Research; Director, Electrophysiology Laboratories and Clinics, University of California, San Francisco

Disclosures

Disclosure: Byron K. Lee, MD, MAS, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Zoll Medical Corporation

Dr Lee does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Lee does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Jeffrey E. Olgin, MD

Gallo-Chatterjee Distinguished Professor of Medicine; Chief, Division of Cardiology; Co-Director, UCSF Heart and Vascular Center, University of California San Francisco

Disclosures

Disclosure: Jeffrey E. Olgin, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Zoll Medical Corporation

Dr Olgin does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Olgin does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Joy P. Marko, MS, APN-C, CCMEP

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships.

Beverly A. Caley, JD

Medical Writer, Caley-Reidenbach Consulting, LLP, Philomath, OR

Disclosures

Disclosure: Beverly A. Caley, JD, has disclosed no relevant financial relationships.

CME Revivewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbot; Medtronic

CME / ABIM MOC / CE

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

Authors: Sunil V. Rao, MD; Jeffrey E. Olgin, MD, FACC; Byron K. Lee MD; Anne B. Curtis, MD, MACP
CME / ABIM MOC / CE Released: 3/27/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 3/27/2019, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, ED physicians, critical care specialists, nurses, NPs, and all clinicians interested in the prevention of SCD.

The goal of this activity is to update participants on the latest guidelines and data regarding the prevention of SCD and application to clinical practice.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Emerging clinical data on the use of wearable cardioverter-defibrillators to prevent SCD
- Latest clinical guidelines on patient selection for SCD
Have greater competence related to
- Use of effective multidisciplinary strategies to prevent SCD in patients at risk

Disclosures

Moderator

Sunil V. Rao, MD

Professor of Medicine, Duke University Medical Center; Section Chief, Cardiology, Durham VA Medical Center, Durham, North Carolina

Disclosures

Disclosure: Sunil V. Rao, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Corindus, Inc.; Medtronic, Inc.; Philips Healthcare; Volcano Corporation

Dr Rao does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Rao does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Anne B. Curtis, MD, MACP

SUNY Distinguished Professor; Charles and Mary Bauer Professor and Chair, Department of Medicine, University at Buffalo, Buffalo, New York

Disclosures

Disclosure: Anne B. Curtis, MD, MACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; Novartis Pharmaceuticals Corporation; Sanofi
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Medtronic, Inc.

Dr Curtis does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Curtis does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Byron K. Lee, MD, MAS

Professor of Medicine; Samuel T. and Elizabeth Webb Reeves Endowed Chair in Arrhythmia Research; Director, Electrophysiology Laboratories and Clinics, University of California, San Francisco

Disclosures

Disclosure: Byron K. Lee, MD, MAS, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Zoll Medical Corporation

Dr Lee does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Lee does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Jeffrey E. Olgin, MD

Gallo-Chatterjee Distinguished Professor of Medicine; Chief, Division of Cardiology; Co-Director, UCSF Heart and Vascular Center, University of California San Francisco

Disclosures

Disclosure: Jeffrey E. Olgin, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Zoll Medical Corporation

Dr Olgin does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Olgin does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Joy P. Marko, MS, APN-C, CCMEP

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships.

Beverly A. Caley, JD

Medical Writer, Caley-Reidenbach Consulting, LLP, Philomath, OR

Disclosures

Disclosure: Beverly A. Caley, JD, has disclosed no relevant financial relationships.

CME Revivewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbot; Medtronic

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / ABIM MOC / CE

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

Authors: Sunil V. Rao, MD; Jeffrey E. Olgin, MD, FACC; Byron K. Lee MD; Anne B. Curtis, MD, MACPFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 3/27/2018

Valid for credit through: 3/27/2019, 11:59 PM EST

processing....

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Sunil V. Rao, MD

Panelists

Anne B. Curtis, MD, MACP

Byron K. Lee, MD, MAS

Jeffrey E. Olgin, MD

Editor(s)

Joy P. Marko, MS, APN-C, CCMEP

Beverly A. Caley, JD

CME Revivewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

CME / ABIM MOC / CE

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

Target Audience and Goal Statement

Disclosures

Moderator

Sunil V. Rao, MD

Panelists

Anne B. Curtis, MD, MACP

Byron K. Lee, MD, MAS

Jeffrey E. Olgin, MD

Editor(s)

Joy P. Marko, MS, APN-C, CCMEP

Beverly A. Caley, JD

CME Revivewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial